Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies
Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies Scale Biosciences (Scale Bio™), a leader in scalable single cell analysis, has announced the launch of its QuantumScale Single Cell RNA kits. These next-generation products are designed to…
Median Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR
Median Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR Median Technologies, a leader in artificial intelligence (AI)-powered software for early cancer diagnostics, has announced its participation in the 2025 European Congress of Radiology (ECR) in…
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1 Healx, a clinical-stage biotech company utilizing AI to advance treatments for rare diseases, has announced that the first patient has been dosed in its Phase 2…
PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients
PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapies, recently announced promising early results from the ongoing FREEDOM-DM1 Phase 1 trial. The trial is investigating…
Seraph 100 May Reduce Tumor Particles in Blood Samples from Pancreatic Cancer Patients
Seraph 100 May Reduce Tumor Particles in Blood Samples from Pancreatic Cancer Patients A recent laboratory study has explored the potential therapeutic benefits of blood purification for patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and…
Bruker Enhances Single-Cell Proteomics and Immunopeptidomics with New Software at US HUPO
Bruker Enhances Single-Cell Proteomics and Immunopeptidomics with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) unveiled significant advancements in 4D-Proteomics™ performance, along with new software and applications aimed at providing deeper biological…
FDA Accepts Bristol Myers Squibb’s Application for Opdivo® + Yervoy® in MSI-High or MMR-Deficient Cancer
FDA Accepts Bristol Myers Squibb’s Application for Opdivo® + Yervoy® in MSI-High or MMR-Deficient Cancer Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) for Opdivo®…
Summit Therapeutics Reports Q4 and 2024 Full-Year Financial and Operational Results
Summit Therapeutics Reports Q4 and 2024 Full-Year Financial and Operational Results Summit Therapeutics Inc. (NASDAQ: SMMT) has provided an update on its operational progress and financial results for the fourth quarter and full year ending December 31, 2024. The company…
Almirall 2024 Results: Surpasses Guidance, Poised for Sustained Growth
Almirall 2024 Results: Surpasses Guidance, Poised for Sustained Growth Almirall, S.A., a global biopharmaceutical company based in Barcelona, has reported strong financial results for the full year of 2024. The company saw a notable increase in total revenue, achieving €990.6…
Samsung Bioepis Launches PYZCHIVA® (Biosimilar to Stelara) in the US
Samsung Bioepis Launches PYZCHIVA® (Biosimilar to Stelara) in the US Samsung Bioepis Co., Ltd. has announced the U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab). PYZCHIVA is approved for treating moderate to severe plaque psoriasis in patients eligible…
Elevance Health Reports Q4 and Full Year 2024 Results, 2025 Outlook
Elevance Health Reports Q4 and Full Year 2024 Results, 2025 Outlook Elevance Health, Inc. (NYSE: ELV) reported strong results for the fourth quarter and full year of 2024, showcasing continued growth and operational improvements despite the challenges facing the healthcare…
Triastek’s D23 (Budesonide Ileum-Targeted Tablet) Shows Positive Clinical Results
Triastek’s D23 (Budesonide Ileum-Targeted Tablet) Shows Positive Clinical Results Triastek has announced that its 3D-printed drug, D23 (Budesonide Ileum-Targeted Tablet), has achieved positive results in a recent clinical trial aimed at treating IgA nephropathy (IgAN). D23 is a budesonide delayed-release…